Keywords: roche, mabthera, improves, survival, nhl, months, new

Roche's MabThera improves survival in NHL at 30 months

Article | 20 December 2004

Print This

New data on Swiss drug major Roche's pioneering monoclonal antibody therapy for non-Hodgkin's lymphoma, presented at the American Society of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in